Johnson & Johnson (JNJ)vsSupernus Pharmaceuticals Inc (SUPN)
JNJ
Johnson & Johnson
$255.88
-3.63%
HEALTHCARE · Cap: $615.36B
SUPN
Supernus Pharmaceuticals Inc
$46.57
-2.43%
HEALTHCARE · Cap: $2.75B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 12506% more annual revenue ($97.93B vs $776.83M). JNJ leads profitability with a 21.5% profit margin vs -3.7%. SUPN appears more attractively valued with a PEG of 1.47. JNJ earns a higher WallStSmart Score of 57/100 (C).
JNJ
Buy57
out of 100
Grade: C
SUPN
Buy52
out of 100
Grade: C-
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 25 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 28.6%
Generating 3.4B in free cash flow
Revenue surging 38.6% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
Moderate valuation
Expensive relative to growth rate
Earnings declined 1.0%
Weak financial health signals
ROE of -2.8% — below average capital efficiency
Currently unprofitable
Operating margin of -3.6%
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.5% and operating margin at 28.6%.
Bull Case : SUPN
The strongest argument for SUPN centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 38.6% demonstrates continued momentum. PEG of 1.47 suggests the stock is reasonably priced for its growth.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : SUPN
The primary concerns for SUPN are Piotroski F-Score, Return on Equity, Profit Margin.
Key Dynamics to Monitor
JNJ profiles as a mature stock while SUPN is a hypergrowth play — different risk/reward profiles.
SUPN carries more volatility with a beta of 0.54 — expect wider price swings.
SUPN is growing revenue faster at 38.6% — sustainability is the question.
JNJ generates stronger free cash flow (3.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (57/100 vs 52/100), backed by strong 21.5% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Supernus Pharmaceuticals Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of diseases of the central nervous system in the United States. The company is headquartered in Rockville, Maryland.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?